ATE371018T1 - LE CELLS (LIVER ENGRAFTING CELLS), ASSAY AND USES THEREOF - Google Patents

LE CELLS (LIVER ENGRAFTING CELLS), ASSAY AND USES THEREOF

Info

Publication number
ATE371018T1
ATE371018T1 AT02742240T AT02742240T ATE371018T1 AT E371018 T1 ATE371018 T1 AT E371018T1 AT 02742240 T AT02742240 T AT 02742240T AT 02742240 T AT02742240 T AT 02742240T AT E371018 T1 ATE371018 T1 AT E371018T1
Authority
AT
Austria
Prior art keywords
cells
liver engrafting
assay
useful
cell
Prior art date
Application number
AT02742240T
Other languages
German (de)
Inventor
Eric Lagasse
Timothy Austin
Original Assignee
Stemcells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23159503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE371018(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stemcells Inc filed Critical Stemcells Inc
Application granted granted Critical
Publication of ATE371018T1 publication Critical patent/ATE371018T1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

A substantially enriched mammalian hepatic liver engrafting cell population is provided. Methods are provided for the isolation and culture of this liver engrafting cell. The progenitor cells are obtained from a variety of sources, including fetal and adult tissues. The cells are useful in transplantation, for experimental evaluation, and as a source of lineage and cell specific products, including mRNA species useful in identifying genes specifically expressed in these cells, and as targets for the discovery of factors or molecules that can affect them.
AT02742240T 2001-06-22 2002-06-21 LE CELLS (LIVER ENGRAFTING CELLS), ASSAY AND USES THEREOF ATE371018T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30053501P 2001-06-22 2001-06-22

Publications (1)

Publication Number Publication Date
ATE371018T1 true ATE371018T1 (en) 2007-09-15

Family

ID=23159503

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02742240T ATE371018T1 (en) 2001-06-22 2002-06-21 LE CELLS (LIVER ENGRAFTING CELLS), ASSAY AND USES THEREOF

Country Status (11)

Country Link
US (3) US7211404B2 (en)
EP (3) EP1406998B1 (en)
JP (2) JP4455876B2 (en)
CN (2) CN1665920A (en)
AT (1) ATE371018T1 (en)
AU (1) AU2002315392B2 (en)
CA (1) CA2451637C (en)
DE (1) DE60221987T2 (en)
DK (1) DK1406998T3 (en)
ES (1) ES2292772T3 (en)
WO (1) WO2003000848A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20050089518A1 (en) * 2001-12-07 2005-04-28 Clarke Michael F. Prospective identification and characterization of breast cancer stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US7838292B1 (en) 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
ES2292772T3 (en) * 2001-06-22 2008-03-16 Stemcells, Inc. LIVER GRAFT CELLS, ANALYSIS, AND ITS USES.
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
EP2003196A3 (en) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
US20050014217A1 (en) * 2003-07-18 2005-01-20 Cytokinetics, Inc. Predicting hepatotoxicity using cell based assays
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
JP4854509B2 (en) * 2004-08-20 2012-01-18 積水メディカル株式会社 Methods for predicting liver metabolism and liver function of drugs in humans
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723112B2 (en) * 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
PT2500360E (en) 2005-10-31 2015-10-15 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer
ATE498005T1 (en) 2005-12-21 2011-02-15 Univ Catholique Louvain ISOLATED LIVER STEM CELLS
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008151283A1 (en) * 2007-06-05 2008-12-11 Oregon Health & Science University Method of expanding human hepatocytes in vivo
EP2179034A1 (en) * 2007-07-20 2010-04-28 Cellartis AB A novel population of hepatocytes derived via definitive endoderm (de-hep) from human blastocysts stem cells
WO2009075856A1 (en) * 2007-12-10 2009-06-18 The Board Of Trustees Of The Leland Stanford Junior University Regenerative dot cells
US9125891B2 (en) * 2008-03-07 2015-09-08 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Lymph nodes as a site for regeneration
ES2663536T3 (en) 2008-09-26 2018-04-13 Oncomed Pharmaceuticals, Inc. Agents that bind to frizzled receptors and uses thereof
US20100227393A1 (en) * 2009-03-06 2010-09-09 Eric Lagasse Liver stem cells: isolation of hepatic progenitor cells from the human gall bladder
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
JPWO2011102532A1 (en) * 2010-02-16 2013-06-17 国立大学法人九州大学 Induced hepatocytes
CN102971337B (en) 2010-04-01 2016-09-21 昂考梅德药品有限公司 FZ combines medicament and application thereof
HK1212216A1 (en) 2012-10-23 2016-06-10 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (en) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods and monitoring of treatment with WNT pathway inhibitors
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP3016665B1 (en) 2013-07-05 2019-09-18 Université Catholique de Louvain Conditioned medium from human adult liver stem cells and its use in the treatment of liver disorders
JP6672603B2 (en) * 2015-03-27 2020-03-25 株式会社豊田中央研究所 Method for evaluating the action between substances and cells
WO2016209865A1 (en) * 2015-06-23 2016-12-29 The Jackson Laboratory Non-hla matched humanized nsg mouse model with patient-derived xenograft
CA3052295A1 (en) * 2017-02-17 2018-08-23 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fat-associated lymphoid clusters as sites for transplantation,tissue regeneration, organogenesis and function for multiple tissues
US20210238257A1 (en) * 2018-04-27 2021-08-05 The Regents Of The University Of California De Novo Formation of the Biliary System by Hepatocyte Transdifferentiation
IL298279A (en) * 2020-04-17 2023-01-01 Council Queensland Inst Medical Res Immune cells with increased function
WO2023060186A1 (en) * 2021-10-07 2023-04-13 Hepatx Corporation Methods of tracking donor cells in a recipient
IL314153A (en) 2022-01-07 2024-09-01 Integriculture Inc Method for culturing liver-derived cells and culture system including liver-derived cells

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6069005A (en) 1991-08-07 2000-05-30 Albert Einstein College Of Medicine Of Yeshwa University Hapatoblasts and method of isolating same
EP0597964A4 (en) 1991-08-07 1994-11-30 Einstein Coll Med PROLIFERATION OF PRECURSORS OF HEPATOCYTEN.
WO1994008598A1 (en) * 1992-10-09 1994-04-28 Advanced Tissue Sciences, Inc. Liver reserve cells
US5459037A (en) 1993-11-12 1995-10-17 The Scripps Research Institute Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
JPH09505206A (en) 1993-11-19 1997-05-27 イェシバ・ユニバーシティ Hepatoblast and its isolation method
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
CA2223492A1 (en) 1995-06-06 1996-12-12 The Whitehead Institute For Biomedical Research Isolation of mammalian hematopoietic stem cells
WO1996040875A1 (en) * 1995-06-07 1996-12-19 Novartis Ag Methods for obtaining compositions enriched for hematopoietic stem cells and antibodies for use therein
US5776683A (en) 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
WO1998017684A2 (en) * 1996-10-25 1998-04-30 Advanced Research & Technology Institute Dna sequences encoding fusions of dna repair proteins and uses thereof
US6129911A (en) * 1998-07-10 2000-10-10 Rhode Island Hospital, A Lifespan Partner Liver stem cell
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US6468794B1 (en) 1999-02-12 2002-10-22 Stemcells, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
DK1144671T3 (en) 1999-02-12 2008-03-17 Stemcells California Inc Enriched central nervous system cell populations
CN1258589C (en) 2000-10-03 2006-06-07 北卡罗来纳大学 Method of isolating bipotent hepatic progenitor cells
WO2002088332A1 (en) * 2001-04-24 2002-11-07 Hokkaido Technology Licensing Office Co.,Ltd. Small liver cell-rich colony, method of preparing the same, method of maturing the same into liver tissue and method of estimating drug function using the matured small liver cell-rich colony
ES2292772T3 (en) * 2001-06-22 2008-03-16 Stemcells, Inc. LIVER GRAFT CELLS, ANALYSIS, AND ITS USES.
US8707400B2 (en) 2007-01-22 2014-04-22 Apple Inc. System and method for implementing an extended authentication and authorization credential store

Also Published As

Publication number Publication date
US7211404B2 (en) 2007-05-01
ES2292772T3 (en) 2008-03-16
JP2009183299A (en) 2009-08-20
AU2002315392A2 (en) 2003-01-08
US20110256625A1 (en) 2011-10-20
EP2388330A1 (en) 2011-11-23
CN1665920A (en) 2005-09-07
DE60221987T2 (en) 2008-05-15
US8283164B2 (en) 2012-10-09
CN101974480A (en) 2011-02-16
DE60221987D1 (en) 2007-10-04
JP2004531270A (en) 2004-10-14
EP1406998A4 (en) 2005-01-19
US20030032184A1 (en) 2003-02-13
EP1406998B1 (en) 2007-08-22
US20070036774A1 (en) 2007-02-15
CA2451637C (en) 2013-04-23
EP1956078A3 (en) 2008-10-29
WO2003000848A3 (en) 2003-03-20
AU2002315392B2 (en) 2008-01-24
WO2003000848A2 (en) 2003-01-03
DK1406998T3 (en) 2007-12-27
EP1956078A2 (en) 2008-08-13
US7811818B2 (en) 2010-10-12
EP1406998A2 (en) 2004-04-14
CA2451637A1 (en) 2003-01-03
EP2388330B1 (en) 2015-05-20
JP4455876B2 (en) 2010-04-21

Similar Documents

Publication Publication Date Title
ATE371018T1 (en) LE CELLS (LIVER ENGRAFTING CELLS), ASSAY AND USES THEREOF
Ross et al. TET enzymes, DNA demethylation and pluripotency
Zhang et al. Derivation of human embryonic stem cells from developing and arrested embryos
Lian et al. Derivation of clinically compliant MSCs from CD105+, CD24− differentiated human ESCs
Park et al. Derivation of primordial germ cells from human embryonic and induced pluripotent stem cells is significantly improved by coculture with human fetal gonadal cells
Yu et al. Human embryonic stem cells reprogram myeloid precursors following cell–cell fusion
Wakayama et al. Equivalency of nuclear transfer‐derived embryonic stem cells to those derived from fertilized mouse blastocysts
Wang et al. Derivation and growing human embryonic stem cells on feeders derived from themselves
Ben-David et al. Expanding the boundaries of embryonic stem cells
Lequarré et al. Cell cycle duration at the time of maternal zygotic transition for in vitro produced bovine embryos: effect of oxygen tension and transcription inhibition
Risley Connexin gene expression in seminiferous tubules of the Sprague-Dawley rat
Ohnuma et al. Enzyme-free passage of human pluripotent stem cells by controlling divalent cations
Scantland et al. The adenosine salvage pathway as an alternative to mitochondrial production of ATP in maturing mammalian oocytes
Skårn et al. Generation and characterization of an immortalized human mesenchymal stromal cell line
Posfai et al. All models are wrong, but some are useful: Establishing standards for stem cell-based embryo models
CA2407505A1 (en) Hepatocyte lineage cells derived from pluripotent stem cells
Umehara et al. Efficient derivation of embryonic stem cells by inhibition of glycogen synthase kinase-3
Mise et al. Differences and similarities in the developmental status of embryo‐derived stem cells and primordial germ cells revealed by global expression profiling
WO2007149447A3 (en) Lung progenitor cells, assays, and uses thereof
Makino et al. Mesenchymal to embryonic incomplete transition of human cells by chimeric OCT4/3 (POU5F1) with physiological co-activator EWS
Ming et al. In vitro culture alters cell lineage composition and cellular metabolism of bovine blastocyst
Kanatsu-Shinohara et al. Enrichment of mouse spermatogonial stem cells by the stem cell dye CDy1
Li et al. Correlation of expression and methylation of imprinted genes with pluripotency of parthenogenetic embryonic stem cells
Spagnoli et al. Guiding embryonic stem cells towards differentiation: lessons from molecular embryology
ATE513851T1 (en) HUMAN GENE CRITICAL TO FERTILITY

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties